Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Acura Pharmaceuticals ( (ACUR) ) has provided an announcement.
On February 6, 13 and March 9, 2026, Acura Pharmaceuticals received three $100,000 loans from major shareholder Abuse Deterrent Pharma, LLC, bringing the total principal outstanding under its consolidated secured promissory note to $9,894,279, with about $1,040,000 in accrued interest as of February 28, 2026, bearing interest at 5.25% and rising to 7.5% on overdue amounts. The funding is being used to support day-to-day operations, but the company warned that without additional financing by the end of March 2026 it may need to sharply scale back or terminate operations and potentially seek bankruptcy protection, risking a complete loss of shareholder value, while AD Pharma and its controller, Mr. Schutte, collectively hold a controlling equity stake through direct ownership and warrants.
More about Acura Pharmaceuticals
Acura Pharmaceuticals, Inc. operates in the pharmaceutical industry, focusing on developing and commercializing products that incorporate technologies such as its LIMITx and Impede platforms. The company’s portfolio and pipeline center on abuse-deterrent and safety-enhanced formulations, targeting pain management and related markets where opioid misuse and safety remain significant concerns.
Technical Sentiment Signal: Sell
Current Market Cap: $33K
For a thorough assessment of ACUR stock, go to TipRanks’ Stock Analysis page.